Loncastuximab
- Generic Name:
- Loncastuximab tesirine-lpyl
- Drug Type:
- CD19-directed antibody and alkylating agent conjugate
- How the Drug is Given:
Intravenously (IV)
- Names:
- Zynlonta™
- Loncastuximab tesirine-lpyl
Indications and Usage
Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Side effects needing medical attention
Most common adverse reactions are thrombocytopenia (low number of platelets), increased gamma-glutamyltransferase (the increase of an enzyme found mostly in the liver), neutropenia (low count of neutrophils), anemia (low number of red blood cells), hyperglycemia (high blood sugar levels), transaminase elevation, fatigue, hypoalbuminemia (low levels of albumin in the blood), rash, edema (swelling caused by fluid trapped in the body’s tissues), nausea, and musculoskeletal pain.